Cancer is generally defined as a disease of aging. With aging, the composition, diversity and
functional characteristics of the gut microbiota occur changes, with a decline of beneficial …

Despite advances in treatment for multiple myeloma, the majority of patients ultimately
develop relapsed disease marked by immune evasion and resistance to standard therapy …

Lymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard
therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine …

Purpose: Vaccination with dendritic cell (DC)/multiple myeloma (MM) fusions has been
shown to induce the expansion of circulating multiple myeloma–reactive lymphocytes and …

Immune dysregulation is a hallmark of clinically active multiple myeloma (MM). Interactions
between malignant clonal cells and immune cells within the bone marrow microenvironment …

Therapeutic cancer vaccines have shown promising efficacy in helping immunotherapy for
cancer patients, but the systematic characterization of the clinical application and the …

Multiple myeloma (MM) is a relapsing clonal plasma cell malignancy and incurable thus far.
With the increasing understanding of myeloma, highlighting the critical importance of the …

Newer immune-based approaches based on recruitment and redirection of endogenous
and/or synthetic immunity such as chimeric antigen receptor T cells or bispecific antibodies …

Given the significance of the immune system and the important role of therapies within the
context of the immune system in plasma cell disorders, the International Myeloma Society …

Background Multiple myeloma (MM) is a hematological malignancy characterized by the
abnormal proliferation of plasma cells. Mitochondrial dysfunction and dysregulated …